Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients

Siew-Wai Fong,3,4,a Barnaby Edward Young,1,2,5 Yi-Hao Chan,3,4 Bernett Lee,4 Siti Naqiah Amrun,3,4 Rhonda Sin-Ling Chee,3,4 Nicholas Kim-Wah Yeo,4 Paul Tambyah,5 Surinder Pada,2 Seow Yen Tan,2 Ying Ding,1 Laurent Renia,3,4 Yee-Sin Leo,1,2,5,7 Lisa F. P. Ng,3,4,7,10 and David Chien Lye,1,2,5

1National Centre for Infectious Diseases, Singapore, 2Tan Tock Seng Hospital, Singapore, 3A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research, Singapore, 4Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, 5Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 6National University Health System, Singapore, 7Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 8Ng Teng Fong General Hospital, Singapore, 9Changi General Hospital, Singapore, and 10Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, United Kingdom

Background. The complications and sequelae of coronavirus disease 2019 (COVID-19) and their effect on long-term health are unclear, and the trajectory of associated immune dysregulation is poorly understood.

Methods. We conducted a prospective longitudinal multicenter cohort study at 4 public hospitals in Singapore. Patients with COVID-19 were monitored for a median of 6 months after recovery from acute infection. Clinical symptoms and radiologic data were collected, along with plasma samples for quantification of immune mediators. The relationship between clinical symptoms and immune cytokine profiles was investigated.

Results. Two hundred eighty-eight participants were recruited, and follow-up data were available for 183, 175, and 120 participants at days 30, 90, and 180 postsymptom onset, respectively. Symptoms related to COVID-19 were present in 31 (16.9%), 13 (7.4%), and 14 (11.7%) at days 30, 90, and 180. In a multivariable model, age >65 years, non-Chinese ethnicity, and the severity of acute infection were associated with increased likelihood of persistent symptoms. Recovered COVID-19 patients had elevated levels of proinflammatory interleukin (IL)-17A, stem cell factor, IL-12p70, and IL-1β and pro-angiogenic macrophage inflammatory protein 1β, brain-derived neurotrophic factor, and vascular endothelial growth factor at day 180 compared with healthy controls. Higher levels of monocyte chemoattractant protein-1 and platelet-derived growth factor-BB were detected in patients with persistent symptoms, versus symptom-free patients.

Conclusions. Approximately 10% of recovered patients had persistent symptoms 6 months after initial infection. Immune cytokine signatures of the recovered patients reflected ongoing chronic inflammation and angiogenesis. Patients with COVID-19 should be monitored closely for emerging long-term health consequences.

Keywords. chronic fatigue; COVID-19; cytokines; long-term; persistent symptoms.

The collective understanding of coronavirus disease 2019 (COVID-19) has evolved rapidly since its emergence, with recognition of the causative virus, evaluation of effective therapeutics, and development of multiple vaccines within the span of 1 year. However, there remain significant unanswered questions with regard to the long-term sequelae associated with COVID-19. Persistent symptoms post-COVID-19 recovery, termed "long COVID," have been reported, describing a clinical phenotype resembling myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), with prominent features of myalgia and fatigue [1, 2]. However, there are limited data as to the frequency of such symptoms or the pathophysiologic mechanisms driving them [3]. Studies have reported dysregulated cytokine release in patients with acute COVID-19 associated with worse disease outcomes [4, 5]. However, the dynamics of cytokine response during recovery and its association with recovery trajectories and long-term outcomes have not been well studied.

Cohort studies tracking COVID-19 patients postrecovery described a high frequency (55% to 87.6%) of persistent symptoms (most commonly fatigue and dyspnea) for up to several months, with an associated decrease in quality of life [6–9]. However, some of these are limited by their single-center study design, small sample sizes, and an absence of correlation with objective biomarkers of disease activity or immune dysregulation to explain persistent symptoms.

In this prospective multicenter cohort study, we aimed to assess the frequency of persistent symptoms up to 6 months across...
a spectrum of confirmed COVID-19 patients with varying initial disease severity. We also studied the longitudinal temporal dynamics of cytokine response, and we determined the relationship of persistent symptoms with immune cytokine profiles during the recovery course.

**METHODS**

**Patient Recruitment**
This was a multicenter study conducted in 4 public hospitals in Singapore that managed COVID-19 inpatients. As part of enhanced surveillance in line with national public health policy, all patients with upper respiratory tract infection or pneumonia are tested for COVID-19 with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR). In addition, several asymptomatic individuals were tested, namely, close contacts of confirmed cases and individuals living in congregate settings (namely, migrant worker dormitories where large outbreaks occurred). Hence, confirmed diagnoses included a large proportion of mild and asymptomatic cases. In the initial phase of the outbreak, all patients with confirmed COVID-19 infection were hospitalized for initial evaluation, regardless of illness severity.

Inclusion criterion was confirmed COVID-19 via SARS-CoV-2-specific PCR and admitted in the study period from January 30 to August 14 2020. There were no predefined exclusion criteria. Patients were invited to participate; however, not all patients could be approached due to resource limitations at the peak of the outbreak. Participants were offered outpatient follow-up postdischarge at 30, 90, 180, 270, and 360 days postsymptom onset (DPSO).

**Clinical Data and Specimen Collection**
Clinical data were extracted from the electronic medical record using a standardized data collection form adapted from the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) case record form [10]. Disease severity was categorized based on worst clinical status during hospital admission: mild (no pneumonia on chest radiographs [CXR] throughout admission), moderate (pneumonia on CXR without hypoxia), and severe (pneumonia with hypoxia [oxygen saturation ≤94%] requiring supplemental oxygen). Severe was further subdivided into noncritical (not requiring intensive care unit [ICU] admission) and critical (requiring ICU admission or mechanical ventilation) for the clinical analysis.

Patients were followed up postdischarge at multiple time points (approximately 30, 90, and 180 DPSO). A standardized symptom questionnaire was administered at each outpatient visit, in addition to an objective assessment and physical examination by a study physician. Plasma samples were collected in cell preparation tubes during hospital admission on days 1, 3, 7, 14, 21, and 28 (if still admitted), and at each outpatient clinic visit on days 30, 90, and 180.

**Multiplex Microbead-Based Immunoassay**
Plasma samples were extracted and treated with a solvent/detergent based on Triton X-100 (1%) for virus inactivation [11]. Immune mediator levels were measured using Cytokine/Chemokine/Growth Factor 45-Plex Human ProcartaPlex Panel 1 (Thermo Fisher Scientific, Waltham, MA) (full details in Supplementary Methods). Cytokine levels were also measured in 24 healthy donor (10 males, 14 females; median age 55 years; details in Supplementary Table S1) plasma samples as baseline controls.

**Statistical Analysis**
Unpaired t-test or Mann-Whitney U test was applied to ascertain significant differences in immune mediator levels between COVID-19 patients and healthy controls at different DPSO and between patients with and without persistent symptoms. A multiple linear regression analysis was conducted to examine the association between plasma cytokines and the presence of symptoms in COVID-19 patients after adjustment for age and disease severity. Two-way repeated measure analysis of variance with Tukey post hoc correction for multiple testing was used to discern the differences between various disease severity groups and timepoints. Plots were generated using GraphPad Prism, version 8 (GraphPad Software, San Diego, CA). ClustVis was used to compute hierarchical clustering and heat map on the immune mediators [12]. In the heat map presentation, the concentrations of immune mediators were scaled between 0 and 1 for visualization. Principal component analysis was performed on the logarithmically transformed concentrations using the singular value decomposition method in ClustVis.

The Mann-Whitney U test was used to compare continuous variables, and the Fisher's exact test was used for categorical variables. Variables that were significantly different between participants with and without persistent symptoms in univariate analysis were selected to construct a multivariable logistic regression model to identify variables independently associated with risk of developing persistent symptoms. P < .05 were considered statistically significant, and all tests were 2-tailed. Analyses were performed using Stata Release 13 (StataCorp, College Station, TX).

**Patient Consent Statement**
Written informed consent was obtained from all study participants. The study protocol was approved by the institutional review board (IRB) (National Healthcare Group Domain Specific Review Board, Study Reference 2012/00917). Healthy donor samples were collected under study numbers 2017/2806 and NUS IRB 04-140.

**RESULTS**

**Patient Recruitment**
Two hundred eighty-eight participants were recruited into the study and consented for outpatient follow-up and serial blood
sample collection (see Supplementary Figure S1 for study recruitment flowchart). Median duration of follow-up in this cohort was 181 days (interquartile range [IQR], 103–191 days; range, 31–295 days). Follow-up visit data were available for 183, 175, and 120 participants at days 30, 90, and 180, respectively. Forty-five (24.6%) participants were female and median age was 44 years old (IQR, 33–56; range, 20–80). Seventy-five (41.0%) participants had at least 1 comorbidity, most commonly hypertension (28.4%) and diabetes mellitus (14.8%). Clinical features, presenting symptoms, and investigations during the index hospitalization are summarized in Table 1. Patients had a range of disease severity during their index hospitalization: 30 (16.4%) asymptomatic, 51 (27.9%) mild, 47 (25.7%) moderate, and 55 (30.1%) severe as defined above.

### Persistent Symptoms and Association With Clinical Features

The number of patients with persistent symptoms at day 30, 90, and 180 were 31 (16.9%), 13 (7.4%), and 14 (11.7%), respectively. The detailed breakdown of individual symptoms is shown in Supplementary Table S2. Symptoms were predominantly pulmonary, with the most common being cough and dyspnea. Participants with persistent symptoms at either day 90 or 180 were older, had a higher Charlson’s comorbidity index, and were more likely to have required supplemental oxygen or ICU admission during their index hospitalization (Table 1). Ethnicity was significantly different between patients with and without persistent symptoms, although we did not capture detailed ethnicity data for those outside the 3 major categories used in Singapore.

### Table 1. Clinical Features and Outcomes During Index Hospitalization for Entire Cohort, and by Patients With and Without Persistent Symptoms at Day 90 or 180

| Variable                                | All Patients (n = 183) | No Persistent Symptoms (n = 161) | Persistent Symptoms at Day 90 or 180 (n = 22) | P Value*   |
|-----------------------------------------|------------------------|---------------------------------|-----------------------------------------------|------------|
| **Demographics**                        |                        |                                 |                                               |            |
| Female sex                              | 45 (24.6)              | 38 (23.6)                       | 7 (31.8)                                      | .43        |
| Age, years                              | 44 (33–56)             | 43 (31–55)                      | 50.5 (39–66)                                  | .042       |
| Ethnicity                               |                        |                                 |                                               | .039       |
| Chinese                                 | 92 (50.3)              | 85 (52.8)                       | 7 (31.8)                                      |            |
| Indian/South Asian                      | 55 (30.1)              | 49 (30.4)                       | 6 (27.3)                                      |            |
| Malay                                   | 14 (7.7)               | 10 (6.2)                        | 4 (18.2)                                      |            |
| Others                                  | 22 (12.0)              | 17 (10.6)                       | 5 (22.7)                                      |            |
| **Comorbidities**                       |                        |                                 |                                               | .039       |
| Charlson’s comorbidity index            | 0 (0–1)                | 0 (0–0)                         | 0 (0–1)                                       |            |
| Any comorbidity                         | 75 (41.0)              | 63 (39.1)                       | 12 (54.6)                                     | .18        |
| Hypertension                            | 52 (28.4)              | 44 (37.3)                       | 8 (36.4)                                      | .45        |
| Diabetes mellitus                       | 27 (14.8)              | 22 (13.7)                       | 5 (22.7)                                      | .33        |
| Ischemic heart disease                  | 13 (7.1)               | 10 (6.2)                        | 3 (13.6)                                      | .19        |
| **Baseline Symptoms**                   |                        |                                 |                                               |            |
| Duration of symptoms before hospitaliz  | 3 (1–6)                | 2 (1–6)                         | 4 (1–7)                                       | .43        |
| Duration of symptoms before hospitaliz  | 3 (1–6)                | 2 (1–6)                         | 4 (1–7)                                       | .43        |
| Fever                                   | 119 (65.8)             | 102 (64.2)                      | 17 (77.3)                                     | .34        |
| Cough                                   | 106 (58.6)             | 90 (56.6)                       | 16 (72.7)                                     | .17        |
| Sputum production                       | 38 (21.0)              | 32 (20.1)                       | 6 (27.3)                                      | .41        |
| Dyspnea                                 | 22 (12.2)              | 18 (11.3)                       | 4 (18.2)                                      | .32        |
| Rhinorrhea                              | 46 (25.4)              | 41 (25.8)                       | 5 (22.7)                                      | >.99       |
| Sore throat                             | 64 (35.4)              | 58 (36.5)                       | 6 (27.3)                                      | .48        |
| Diarrhea                                | 28 (15.5)              | 20 (12.6)                       | 8 (36.4)                                      | .009       |
| Myalgia                                 | 32 (17.7)              | 27 (17.0)                       | 5 (22.7)                                      | .55        |
| Asymptomatic                            | 30 (16.4)              | 27 (16.8)                       | 3 (13.6)                                      | >.99       |
| **Clinical Outcomes**                   |                        |                                 |                                               |            |
| CXR opacities                           | 101 (55.2)             | 85 (52.8)                       | 16 (72.7)                                     | .11        |
| Supplemental oxygen                     | 54 (29.5)              | 42 (26.1)                       | 12 (54.6)                                     | .011       |
| ICU admission                           | 33 (18.0)              | 25 (15.5)                       | 8 (36.4)                                      | .033       |
| Mechanical ventilation                  | 11 (6.0)               | 8 (5.0)                         | 3 (13.6)                                      | .13        |
| **Severity**                            |                        |                                 |                                               | .040       |
| Mildb                                   | 81 (44.3)              | 75 (46.6)                       | 6 (27.3)                                      |            |
| Moderate                                | 47 (25.7)              | 43 (26.7)                       | 4 (18.2)                                      |            |
| Severe                                  | 55 (30.1)              | 43 (26.7)                       | 12 (54.6)                                     |            |

**Abbreviations:** CXR, chest radiograph; ICU, intensive care unit.

**NOTE:** Values reported as number (percentage) for categorical variables and median (interquartile range) for continuous variables. Bold text indicates P values < .05.

*Comparing patients without persistent symptoms against patients with persistent symptoms at day 90 or day 180.

*Including asymptomatic patients.
In the multivariable model imputing age, sex, ethnicity, Charlson's comorbidity index, and disease severity; age group >65 years old, non-Chinese ethnicity, and critical illness severity (defined as ICU admission or requiring mechanical ventilation) during the index admission were independently associated with increased odds of persistent symptoms (Table 2).

Follow-up CXRs were reviewed for all patients with an initial abnormal CXR, and the latest abnormal CXR date was recorded in relation to the symptom onset date. Median time to resolution of CXR opacities was 14 days (IQR, 9–32; range, 1–195). However, because CXRs were not systematically repeated in a protocolized manner, there was a wide range of durations between follow-up CXRs. Hence, we did not further analyze this.

**Longitudinal Cytokine Responses in Recovered Coronavirus Disease 2019 Patients**

There was a prominent increase in levels of inflammation-associated markers interleukin (IL)-6, IL-8, interferon (IFN)-α, IL-18, IL-1RA, monocyte chemoattractant protein (MCP)-1, and macrophage inflammatory protein (MIP)-1α at the acute phase of disease, which subsided significantly over the 30-day or 90-day period (Figure 1A). Compared with healthy controls, at day 90, recovered patients across all severity strata had higher levels of multiple growth factors, cytokines, and chemokines. Recovered patients who had severe illness demonstrated higher levels of hepatocyte growth factor (HGF) compared with healthy controls (Figure 1C, Supplementary Table S3). Overall, the 180-day profile of recovered COVID-19 patients revealed signs of ongoing chronic inflammation (high levels of IL-17A, IL-12p70, stem cell factor [SCF], and IL-1β) and endothelial repair and angiogenesis (high levels of BDNF, MIP-1β, and VEGF) (Figure 1C, Supplementary Table S3). It is notable that there were no significant differences in the levels of these immune mediators between patients with different disease severity.

The temporal changes of systemic cytokine profiles were further profiled by longitudinal analysis of plasma immune mediators from the acute phase to day 180 in 64 patients who provided blood samples across all 4 time points, stratified by initial disease severity. The levels of inflammation-associated IL-6, IP-10, IL-18, and MCP-1 significantly decreased at the second timepoint (14–75 DPSO) in patients across all severity strata (Supplementary Figure S3). Among immune mediators that remained high at day 180, levels of BDNF, MIP-1β, VEGF-A, and IL-12p70 were already increased in the early phase of infection, which persisted over time (Figure 2). It is notable that persistent elevation of HGF was only observed in patients with initial severe infection. Levels of VEGF-D, IL-17A, and SCF increased slowly during convalescent phase and remained high at day 180 (Figure 2).

**Comparison of Cytokine Responses Between Patients With and Without Persistent Symptoms**

We next examined the relationship between systemic cytokine profiles and persistent symptoms. At day 30, there was a significantly higher level of MCP-1 in patients with persistent

### Table 2. Logistic Regression Analysis of Variables Associated With Persistent Symptoms at 90 or 180 days

| Variable                      | Odds Ratio (95% CI) | P-Value | Adjusted Odds Ratio (95% CI) | P-Value |
|-------------------------------|--------------------|---------|-----------------------------|---------|
| **Univariable Model**         |                    |         |                             |         |
| Age Group                     |                    |         |                             |         |
| <45 years old                 | Ref                | N.A.    | Ref                         | N.A.    |
| 45–65 years old               | 1.25 (.44–3.51)    | .67     | 1.66 (.49–5.60)             | .41     |
| >65 years old                 | 6.67 (1.89–23.57)  | .003    | 8.75 (1.68–48.34)           | .013    |
| Female sex                    | 1.52 (.57–4.01)    | .40     | 3.05 (.88–10.56)            | .078    |
| Ethnicity                     |                    |         |                             |         |
| Chinese                       | Ref                | N.A.    | Ref                         | N.A.    |
| Indian/South Asian            | 1.62 (.51–5.11)    | .41     | 5.49 (1.15–26.14)           | .033    |
| Malay                         | 4.74 (1.18–19.09)  | .028    | 5.23 (1.94–29.22)           | .059    |
| Others                        | 3.71 (1.04–13.18)  | .043    | 12.14 (2.99–48.16)          | .001    |
| Charlson's comorbidity index ≥ 1 | 2.25 (.89–5.69) | .087    | 1.48 (.46–4.76)             | .51     |
| Severity                      |                    |         |                             |         |
| Mild                          | Ref                | N.A.    | Ref                         | N.A.    |
| Moderate                      | 1.05 (1.28–3.95)   | .94     | 1.23 (1.28–5.32)            | .78     |
| Severe                        | 3.24 (1.13–9.28)   | .029    | 3.10 (1.91–10.62)           | .072*   |

Abbreviations: CI, confidence interval; N.A., not applicable; Ref, reference variable. 
NOTE: Patients who only had data up to 30 days were excluded from logistic regression analysis. Bold text indicates P values < .05.

*Further stratification into noncritical severe (not requiring intensive care unit [ICU] admission) and critical (requiring ICU admission or mechanical ventilation) showed critical severity was independently associated with persistent symptoms in the multivariable model (adjusted OR, 4.23; 95% CI, 1.02–17.56; P = .047).
Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered COVID-19 Patients • OFID • 5

Figure 1. Plasma immune mediator levels of coronavirus disease (COVID-19) patients at 90 and 180 days postsymptom onset. Concentrations of 45 immune mediators were quantified using a 45-plex microbead-based immunoassay. (A) Heatmap of immune mediator levels in plasma samples of COVID-19 patients at first 2 weeks, 30 days, 90 days, and 180 days postsymptom onset. Each color represents the relative concentration of a particular analyte. Blue and red indicates low and high concentration, respectively. (B) Principal component analysis of 45 immune mediator levels analyzed in 101 COVID-19 patients (mild, n = 38; moderate, n = 34; severe, n = 29) at 180 days postsymptom onset and healthy controls (HC) (n = 24). PC1 explains 17.7% of the variation, whereas PC2 explains 15.7% of the variation; color denotes different groups of patients and healthy donors. (C) Profiles of immune mediators that are significantly higher in COVID-19 patients at 180 days postsymptom onset compared with HC are illustrated as scatter plots. Immune mediator levels in plasma fraction samples of COVID-19 patients collected during 180-day follow up (median 186 days postillness onset) were compared with the levels in HC. Unpaired t test was performed on the logarithmically transformed concentration (*P < .05; **P < .01; ***P < .0001). Immune mediator levels for HC are indicated by the black dotted line. Patient samples with concentration out of measurement range are presented as the value of logarithm transformation.

DISCUSSION

In this multicenter cohort study, COVID-19 was associated with a significant but overall low frequency of persistent symptoms after resolution of the acute illness: 7.4% and 11.7% at 90 and 180 days, respectively. This is lower compared with other similar cohort studies in Italy, France, the United Kingdom, and China, which reported persistent symptoms in 55% to 87.6% of patients [6–9]. Despite the proportion of severe initial infections being similar in our cohort compared with these cohorts (18% admitted to ICU compared with 12.6%, 20%, 32%, and 4%, respectively) [6–9], we showed that cytokine expression
Epidemiologic studies of ME/CFS demonstrated differences in incidence rates across ethnic groups [13], which may explain the difference between various disease severity groups and time points (*P < .05, **P < .01, ***P < .001). Mean levels of immune mediators for healthy controls are indicated by the black dotted line. Patient samples with concentration out of measurement range are presented as the value of logarithm transformation of limit of quantification. BDNF, brain-derived neurotrophic factor; HGF, hepatocyte growth factor; IL, interleukin; MIP, macrophage inflammatory protein; SCF, stem cell factor; VEGF, vascular endothelial growth factor.

Our longitudinal analyses of cytokine responses in recovered COVID-19 patients revealed subclinical changes potentially underpinning for proinflammatory cytokines was only marginally different in follow-up samples for those with initial severe disease compared with asymptomatic and mildly infected individuals, suggesting that other reasons are important for the development of persistent symptoms.

For example, differences in demographics and ethnicity may explain this discordance in the frequency of persistent symptoms. Epidemiologic studies of ME/CFS demonstrated differences in incidence rates across ethnic groups [13], which may be explained by genetic differences because specific human leukocyte antigen alleles were associated with ME/CFS [14]. Indeed, in our cohort, there were significant differences in the frequency of persistent symptoms across ethnic groups (with higher proportions in the “Others” category, which included those of European descent), which merits further investigation. Although Huang et al [9] found a high proportion (76%) of persistent symptoms in a Chinese cohort, they had a much higher proportion of patients with severe disease (75% requiring supplemental oxygen), which may explain the difference between our cohorts.

Furthermore, we had a higher proportion of patients (16.4%) with asymptomatic index infection. This may result in an underestimation of the frequency of persistent symptoms at follow-up for patients with symptomatic index infection.

Nevertheless, the finding that 3 of these asymptomatic patients went on to develop persistent symptoms later on, coupled with cytokine analysis showing abnormal cytokine profiles even in asymptomatic patients, is novel and stresses the importance of disregarding patients with asymptomatic index infection. We found that COVID-19 patients had distinct systemic cytokine profiles at up to 6 months postsymptom onset compared with healthy controls, regardless of initial severity of illness or persistent symptoms. Levels of proinflammatory T cell-associated cytokines such as IL-17A, IL-12p70, IL-1β, and SCF were elevated and increased postdischarge. Interleukin-12p70, SCF, and IL-17A have been found to be associated with chronic inflammatory diseases such as ME/CFS and inflammatory spondyloarthropathy [15, 16]. Liu et al [17] found that convalescent individuals still experienced enhanced CD4 and CD8 T-cell activation and proliferation, along with a contraction of NKT-like cells 3 months after resolving SARS-CoV-2 infection, whereas Bergamaschi et al [18] observed that persistent inflammation correlates with activation of cell metabolic pathways. This sustained immune and metabolic dysregulation may be a driver of chronic inflammation in recovered COVID-19 patients.

Our longitudinal analyses of cytokine responses in recovered patients revealed subclinical changes potentially underpinning...
Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered COVID-19 Patients

Regulators of endothelial activation such as VEGF, BDNF, and MIP-1β could promote atherosclerosis and potentially result in silent coronary artery disease [19–22]. Convalescent patients were found to have pronounced endothelial activation hallmarks, abnormal cardiovascular imaging findings, and ongoing myocardial inflammation after COVID-19 recovery [23, 24]. Our findings of persistent elevation of pro-angiogenic factors warrants long-term monitoring and assessment of potential cardiovascular effects.

Platelet-derived growth factor-BB, a potent chemotactic growth factor that stimulates the growth and migration of lung fibroblasts, has been implicated in the pathogenesis of pulmonary fibrosis [25], whereas elevated levels of MCP-1 in patients with chronic obstructive pulmonary disease play a role in inducing emphysema [26]. Increased levels of PDGF-BB and MCP-1 in patients with persistent respiratory symptoms suggest a mechanism for chronic lung disease, and therapeutic strategies targeting these immune mediators could be beneficial to ameliorate the progression of pulmonary symptoms in recovered COVID-19 patients [27, 28].

There are several limitations to our study. First, although we correlated the presence of persistent symptoms with cytokine features, we did not systematically evaluate end-organ involvement using functional assessments such as lung function tests, exercise tolerance scales, or detailed imaging. Second, symptom questionnaires were qualitative, and we did not utilize quantitative indices to measure impact on quality-of-life or functional status; thus, there may be intersubject variability and subjectivity. Third, we did not have a control group to compare the frequency of persistent symptoms following other respiratory viruses to determine whether COVID-19 is associated with an increased risk of persistent symptoms. We also cannot be certain whether reported symptoms are due to COVID-19 or other conditions. Finally, a significant proportion of patients were lost to follow-up, which may introduce an element of selection bias. However, it is likely that those who defaulted further follow-up were more likely to not have persistent symptoms, because those with persistent symptoms would be expected to have continued monitoring.

**Figure 3.** Plasma immune mediator levels in coronavirus disease (COVID-19) patients with symptoms at 1 month, 3 months, and 6 months postsymptom onset. (A) Profiles of immune mediators that are significantly higher in COVID-19 patients with symptoms at 30 days (n = 28), 90 days (n = 12), and 180 days (n = 8) postsymptom onset are illustrated as box plots. Immune mediator levels in plasma fraction samples of COVID-19 patients with respiratory symptoms collected during 30, 90, and 180-day follow-up were compared with the levels in those without respiratory symptoms (30 days, n = 72; 90 days, n = 155; 180 days, n = 87). Mann-Whitney U-test was performed on the logarithmically transformed concentration (*P < .05; **P < .01). Median levels of immune mediator in healthy controls (HC) are indicated by the black dotted line. Patient samples with concentration out of measurement range are presented as the value of logarithm transformation of limit of quantification. (B) Dynamic changes of plasma monocyte chemoattractant protein (MCP)-1 and platelet-derived growth factor (PDGF-BB) in COVID-19 patients with (n = 4) and without persistent symptoms (n = 77) across 4 time periods, including 1 to 14 days, 15 to 75 days, 16 to 150 days, and >150 days postsymptom onset.
seeking medical care, and as such selection bias is more likely to have overestimated the frequency of persistent symptoms.

Differences among study cohorts make comparison of persistent COVID-19 symptoms difficult, and a consensus case definition should be developed to standardize diagnosis and data collection to better understand this condition. The relatively nonspecific and subjective nature of persistent symptoms makes the clinical picture harder to define. Establishing a causal link between COVID-19 and persistent symptoms remains challenging in the absence of a control group of non-COVID-19 patients. The presence of persistent symptoms posthospitalization has been described in many conditions, including community-acquired pneumonia [29], severe acute respiratory syndrome (SARS) [30, 31], Middle East respiratory syndrome [32], and a general "post-ICU syndrome" [33, 34].

Nevertheless, the persistent symptoms of COVID-19 should not be overlooked, given (1) the significant impact on quality-of-life and functional status and (2) a potentially huge impact on costs and resource utilization. It is clear that there are long-lasting immune changes triggered by COVID-19 infection, and although we could not establish a strong association between these immune signatures and persistent symptoms in our study, it is an intriguing signal that requires further study.

Further questions remain regarding persistent COVID-19. Although we have demonstrated differences in the immune signatures of recovered COVID-19 patients, the mechanism behind this remains unclear. Prolonged viral shedding of SARS-CoV-2 nucleic acid has been observed from the respiratory tract, although multiple studies have shown that these are largely nonviable genetic material [4, 35]. A postmortem pathologic study showed evidence of persistent viral infection of pneumocytes and endothelial cells in patients who died of severe COVID-19, even later in the illness up to 30–40 days postinfection [36]. The persistently elevated levels of cytokines in our cohort involved in endothelial repair and angiogenesis (MIP-1β, BDNF, and VEGF-A) are consistent with a hypothesis of active endothelial inflammation even in the absence of persistent symptoms. Viral persistence in sanctuary sites could elicit an ongoing immune response, providing a pathophysiologic basis for endothelial dysfunction and some of the symptoms observed in persistent COVID-19.

CONCLUSIONS

In conclusion, we have shown that there remain durable changes in immune signatures in recovered COVID-19 patients, and this is seen across the entire spectrum of disease severity at index presentation. Some of these dysregulated immune changes may underlie the pathophysiologic mechanisms of persistent COVID-19 symptoms in a subset of recovered patients. Further large multicenter and international cohort studies are needed to better characterize the clinical features, risk factors, and pathophysiology behind persistent COVID-19.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments

We thank all clinical and nursing staff who looked after patients with coronavirus disease 2019 (COVID-19) in participating hospitals; the individuals who participated in this study and donated their clinical data and biological samples; and the research team at Singapore Infectious Disease Clinical Research Network and Infectious Disease Research and Training Office for coordinating patient recruitment, sample collection, and shipment. We are grateful to staff from the Singapore Immunology Network (SIgN) Multiplex Analysis of Proteins (MAP) platform for their assistance in running multiplex microbeads-based immunoassay and staff at the Duke-NUS Medical School ABSL3 for processing patient samples.

Author contributions. S. W. X. O. and S.-W. F. have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. B. E. Y., Y.-S. L., and D. C. L. designed the study protocol. S. W. X. O., B. E. Y., P. T., S. P., S. Y. T., and Y. D. collected the data. S. W. E., Y.-H. C., B. L., S. N. A., R. S.-L. C., N. K.-W. Y., L. R., and L. F. P. N. conducted the laboratory investigations. S. W. X. O. and S.-W. F. conducted the data analysis and drafted the manuscript. L. R., Y.-S. L., L. F. P. N., and D. C. L. provided overall supervision. All authors read and approved the final manuscript.

Disclaimer. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Financial support. Recruitment of study participants and sample collection was funded by the Singapore National Medical Research Council COVID-19 Research Fund (COVID19RF-001, COVID19RF-060) and A*STAR COVID-19 Research funding (H/20/04/g1/006). The SIgN Immunomonitoring Platform is supported by a BMRC IAP 311006 grant and BMRC transition funds (H16/99/b0/011). The SIgN MAP platform was supported by a grant from the National Research Foundation, Immunomonitoring Service Platform (NRF2017_SISFP09) from the National Research Foundation Singapore.

Potential conflicts of interest. B. E. Y. reports personal fees from Roche and Sanofi, outside the submitted work. D. C. L. was on the Gilead COVID-19 advisory panel without taking personal honorarium. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Mahase E. Covid-19: what do we know about “long covid”? BMJ 2020; 370:m2815.
2. Marshall M. The lasting misery of coronavirus long-haulers. Nature 2020; 585:339–41.
3. Yelin D, Wirtheim E, Vetter P, et al. Long-term consequences of COVID-19: research needs. Lancet Infect Dis 2020; 20:1115–7.
4. Young BE, Ong SWX, Ng LPP, et al. Viral dynamics and immune correlates of COVID-19 disease severity. Clin Infect Dis 2020; doi:10.1093/cid/ciaa1280.
5. Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med 2020; 8:1233–44.
6. Carfi A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324:603–5.
7. Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect 2020; 81:e4–6.
Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered COVID-19 Patients • OFID • 9

8. Halpin SJ, McVor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol 2021; 93:1013–22.

9. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397:220–32.

10. COVID-19 CRF - ISARIC. https://isaric.tghn.org/novel-coronavirus/. Accessed 17 December 2020.

11. Darnell ME, Taylor DR. Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products. Transfusion 2006; 46:1770–7.

12. Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap. Nucleic Acids Res 2015; 43:W566–70.

13. Dinos S, Khoshaba B, Ashby D, et al. A systematic review of chronic fatigue, its syndromes and ethnicity: prevalence, severity, co-morbidity and coping. Int J Epidemiol 2009; 38:1554–70.

14. Lande A, Fluge Ø, Strand EB, et al. Human leukocyte antigen alleles associated with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Sci Rep 2020; 10:5267.

15. Montoya JG, Holmes TH, Anderson JN, et al. Cytokine signature associated with disease severity in chronic fatigue syndrome patients. Proc Natl Acad Sci U S A 2017; 114:E7150–8.

16. Taams LS, Steel KIA, Srenathan U, et al. IL-17 in the immunopathogenesis of spondyloarthritis. Nat Rev Rheumatol 2018; 14:453–66.

17. Liu J, Yang X, Wang H, et al. Analysis of the long-term impact on cellular immunity in COVID-19 recovered individuals reveals a profound NKT cell impairment. mBio 2021; 12:e00085–21.

18. Bergamaschi L, Mescia F, Turner L, et al. Early immune pathology and persistent dysregulation characterise severe COVID-19 [preprint]. medRxiv 2021; 2021.01.11.20248765.

19. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2011; 2:1097–105.

20. Kermani P, Hempstead B. Brain-derived neurotrophic factor: a newly described mediator of angiogenesis. Trends Cardiovasc Med 2007; 17:140–3.

21. Chang TT, Lin LY, Chen JW. Inhibition of macrophage inflammatory protein-1β improves endothelial progenitor cell function and ischemia-induced angiogenesis in diabetes. Angiogenesis 2019; 22:53–65.

22. Camaré C, Pucelle M, Nègre-Salvayre A, Salvayre R. Angiogenesis in the atherosclerotic plaque. Redox Biol 2017; 12:18–34.

23. Chioe FW, Fong S-W, Young BE, et al. Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. Elife 2021; 10:e64909.

24. Puntmann VO, Carej ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; 5:1265–73.

25. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004; 15:255–73.

26. Di Stefano A, Cocci T, Roda E, et al. Blood MCP-1 levels are increased in chronic obstructive pulmonary disease patients with prevalent embolysma. Int J Chron Obstruct Pulmon Dis 2018; 13:1691–700.

27. Kardas G, Dzaryańska-Kardas A, Marynowski M, et al. Role of platelet-derived growth factor (PDGF) in asthma as an immunoregulatory factor mediating airway remodeling and possible pharmacological target. Front Pharmacol 2020; 11:47.

28. Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies. Pulm Med 2020; 2020:6175964.

29. Metlay JP, Fine MJ, Schulz R, et al. Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. J Gen Intern Med 1997; 12:423–30.

30. Lam MH, Wing YK, Yu MW, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med 2009; 169:2142–7.

31. Ngai JC, Ko FW, Ng SS, et al. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirrology 2010; 15:543–50.

32. Ahmed H, Patel K, Greenwood DC, et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis. J Rehabil Med 2020; 52:jrm00063.

33. Bein T, Weber-Carstens S, Apfelbacher C. Long-term outcome after the acute respiratory distress syndrome: different from general critical illness? Curr Opin Crit Care 2018; 24:35–40.

34. Myers EA, Smith DA, Allen SR, Kaplan LJ. Post-ICU syndrome: rescuing the unrecognised. JAAPA 2016; 29:34–7.

35. Bullard J, Dust K, Funk D, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis 2020; 71:2663–6.

36. Bussani R, Schneider E, Zentilin L, et al. Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. EBioMed 2020; 61:103104.